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Abnormal angiogenesis is a well characterized complication in diabetic retinopathy and is now recognized as a feature of diabetic
nephropathy. The primary growth factor driving the increased angiogenesis in diabetic retinopathy and nephropathy is vascular
endothelial growth factor (VEGF). While VEGF is considered an important growth factor for maintaining glomerular capillary
integrity and function, increased action of VEGF in diabetic renal disease may carry adverse consequences. Studies by our group
suggest that the effects of VEGF are amplified in the setting of endothelial dysfunction and low nitric oxide (NO) levels, which are
a common feature in the diabetic state. The lack of NOmay amplify the effects of VEGF to induce inflammation (via effects on the
macrophage) and may lead to dysregulation of the vasculature, exacerbating features of diabetic renal disease. In this review, we
summarize how an “uncoupling” of the VEGF-NO axis may contribute to the pathology of the diabetic kidney.
1. Abnormal Angiogenesis Is a Characteristic
Feature of Diabetic Nephropathy
The first description documenting abnormal angiogenesis in
the diabetic kidney is from a 1987 study by Østerby and
Nyberg [1]. These authors reported that patients with long-
term type 1 diabetes showed an increase in capillaries in
the renal biopsy that were both within and surrounding
the glomeruli. Other investigators later demonstrated similar
findings in type 2 diabetic patients with kidney disease [2, 3].
In these patients, 1–5%of glomerular capillaries were found to
contain aberrant vessels. Interestingly, the abnormal vessels
were also present in Bowman’s capsule or in the glomerular
vascular pole, presenting as an “extra efferent arteriole” [1, 4].
A Japanese research group examined human kidney samples
from 94 patients with diabetes and performed detailed
analyses of serial sections using computer-generated three
dimensional images [5]. They reported that the abnormal
vessels were often found to be anastomosed to the lobular
structure of the intraglomerular capillary network, mainly to
afferent branches through the widened vascular hilus, while
the distal end of the vessels was connected to the peritubular
capillary. Morphologically the endothelial cells were often
swollen early in the disease only to become shrunken as
diabetes progressed [6, 7]. Another interesting finding was
that the aberrant proliferation of blood vessels was not
infrequent in diabetic patients even during the first two years
of disease [5], indicating that the development of these vessels
could occur in the early phases of diabetic nephropathy.
Similar to human diabetic kidney disease, some diabetic
animal models also developed excessive numbers of capillary
vessels. For instance, Nyengaard and Rasch identified abnor-
mal glomerular capillaries in an animal rat model induced by
streptozotocin [8]. The db/db mice also exhibit an increase
in endothelial cell number and an elongation of capillaries in
their glomeruli [9, 10]. However, it should be noted that in
the later stages of diabetic nephropathy, there is often a loss
of capillaries in both human and animal models [2, 11, 12]. A
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decrease in VEGF expression in advanced stage of diabetic
nephropathy could account for such capillary loss [2, 11, 12].
2. VEGF Is Deleterious in Diabetic Kidney as
Opposed to Nondiabetic Renal Disease
VEGF is a critical growth factor for endothelial cells, espe-
cially in the kidney. Podocytes and proximal tubular epithelial
cells are likely major sources for VEGF which binds to
receptors on the glomerular and peritubular endothelial cells,
respectively. Under conditions in which local VEGF levels fall
acutely, a loss of capillaries occurs, leading to lesions that may
appear similar to a thrombotic microangiopathy. In progres-
sive nondiabetic kidney disease, a loss of VEGF may occur
more slowly, leading to a loss of capillaries in association with
reduced renal function and fibrosis. Under these cases, the
administration of VEGF can stimulate capillary growth and
improve the kidney lesions [13–15]. Given these facts, VEGF
seems to be indispensable for renal normal physiology and a
loss of VEGF may play an important role in both acute and
chronic kidney diseases.
In contrast, an excessive amount of VEGF is likely a
contributory factor for diabetic kidney disease. This nature
was first shown in a 1999 study, in which an increase in
renal VEGF/VEGFR2 expression was observed in strepto-
zotocin (STZ) induced diabetic rat [16]. Likewise, we also
documented an increase in glomerular VEGF expression,
which was associated with diabetic glomerular injury in the
diabetic eNOSKO mice [17]. These findings were confirmed
in human diabetic nephropathy, in which VEGF was found
to be increased in both renal biopsies and urine [3, 18].
To determine its role in diabetic kidney disease, several
investigators have attempted to inhibit the excessive VEGF.
For instance, anti-VEGF antibody was the first to be tested
while a pharmacological inhibitor was also used in the several
types of diabetic rodents, including STZ induced diabetic
rats, db/dbmice, and Zucker rats [19, 20]. In general, blocking
VEGF consistently demonstrated protective effects, such as
a reduction in urine albumin excretion, an inhibition in
glomerularmatrix expansion, and podocyte protection. Like-
wise, Ku and colleagues utilized a molecular technology to
overexpress sFlt-1 (a soluble VEGFR1) in podocytes to locally
block VEGF function in STZ diabetic mice. This treatment
had similar beneficial effects as systemic VEGF inhibitors
[21]. While these studies unfortunately did not examine
the direct effect of such therapies on the development of
abnormal angiogenesis, they do provide supporting evidence
that excessive VEGF expression may contribute to diabetic
nephropathy.
3. Why Is VEGF Deleterious in
Diabetic Nephropathy?
While VEGF is capable of producing several biological
factors, one of the most important factors could be the
endothelial nitric oxide (NO) because endothelial NO was
found to potently protect the vasculature in several ways,
including stimulating vascular relaxation and having both
anticoagulation and anti-inflammatory effects. As such, it is
likely that the vascular protections of VEGF might be via
stimulating NO production. In contrast, a lack of NO could
turn VEGF to be deleterious in vascular system. Zhao et
al. reported that blocking NO production induced vascu-
lar remodeling and inflammation along with upregulation
of VEGF. Importantly, blocking VEGF action resulted in
ameliorating such injury, indicating that VEGF could be
deleterious in vascular system in the absence of NO [22].
Thus, endothelial NO could be a key factor to regulate VEGF
function.
How can NO regulate VEGF action? In 2001, Dunk and
Ahmed addressed this issue with the tumor epithelial cells.
They concluded that cell proliferation is mediated by
VEGFR2 while VEGFR1 stimulation resulted in NO produc-
tion, suggesting that these two actions are independently
regulated by two different receptors. They also found that
NO, which was mediated by VEGFR1 stimulation, could
negatively regulate VEGFR2-mediated mitogenesis [23].
Given these facts, we hypothesized that the combination of
increased VEGF with an impaired endothelial NO response
might play a role in the abnormal angiogenesis observed in
diabetes (Figure 1).
4. Endothelial NO Availability Is Reduced in
Diabetic Condition
Is NO bioavailability reduced in the diabetic kidney? In this
regard, many studies have documented that diabetes is asso-
ciated with a reduction in NO bioavailability. The underlying
mechanisms appear to be diverse, but many diabetes-related
factors are likely involved, including hyperglycemia [24],
advanced glycation end-products [25], uric acid [26], ADMA
[27] and oxidative stress [28], and are actually able to reduce
NO bioavailability.
Gene polymorphisms in endothelial nitric oxide synthase
(eNOS) may be also a factor, which is involved in regulating
NO levels [29] because eNOS is the principal enzyme pro-
ducing NO in endothelial cells. Based on such assumption,
eNOS gene polymorphisms have been examined in diabetic
patients by several investigators. However, the role of such
genetic alteration remains unclear as some [30–33], but not
all, studies [34–37] documented a positive association of
specific eNOS polymorphisms with diabetic nephropathy.
Alternatively, Hohenstein et al. performed immunohisto-
chemistry to investigate eNOS expression in type 2 diabetic
patients and found that eNOS expression was increased
in glomeruli in patients with diabetes [38]. Similarly, STZ
induced diabetic rats were found to exhibit an increase in
eNOS expression in endothelial cells in both the afferent
arterioles and the glomerulus [39]. While these lines of evi-
dences do not meet our assumption, we should be aware that
eNOS expression is not always correlated with its activity. In
general, the production of NO requires eNOS to be “coupled”
while, in turn, “uncoupled” eNOS generates superoxide as
opposed to NO. Brodsky et al. found that high glucose
induces uncoupling of eNOS,which causes a reduction inNO
bioavailability and an increase in superoxide production [40].
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Figure 1: Central role of NO in regulating VEGF system in endothelial cells. In endothelium, VEGFR1 contributes to NO production
whereas endothelial cell proliferation is regulated by VEGFR2. VEGFR1 is also expressed in macrophage as well as VSMC. In the normal
setting, endothelial cells produce NO, which negatively regulates endothelial cell proliferation, macrophage migration, and VSMC activation
to maintain the well balanced vascular integrity. In contrast, endothelial NO bioavailability is reduced in certain physiological conditions,
such as diabetes. In the case that NO bioavailability is reduced in endothelium, a compensatory increase in VEGF expression as well as a
disruption of negative regulation in vascular system in response to VEGF occurs. As a consequence, VEGF engages VEGFR2 to enhance
endothelial cell proliferation while VEGFR1 on macrophage and VSMC can be activated to induce vascular injury.
Likewise, Komers et al. found that eNOS in diabetic kidney
may also exist in the uncoupled form where it localized to
the cytosolic fraction. Since eNOS activation also requires
the translocation into plasmamembrane in the coupled form
[41], it is likely that the upregulated eNOS in diabetes might
be an inactivated form.
5. Uncoupling of VEGF with Endothelial
NO Causes Abnormal Angiogenesis in
the Diabetic Kidney
Regarding such notion, our first insight came from studying
STZ induced diabetes in themouse lacking eNOS (eNOSKO)
[12]. VEGF expression was increased in both diabetic wild
type and diabetic eNOSKOmice. Since eNOS was genetically
deleted, the kidney exhibited the condition of being upreg-
ulated. However, diabetic eNOSKO mice developed much
more severe clinical manifestations that resembled overt
diabetic nephropathy in humans. For example, this mouse
was found to develop hypertension, massive albuminuria,
and renal dysfunction [12]. This mouse model also exhibited
higher mortality rates from progressive renal disease [12,
42]. Histological manifestations of diabetic eNOSKO mice
also mimic those of human diabetic nephropathy. In fact,
this mouse model developed not only the early manifesta-
tions, such as mesangial expansion and glomerular basement
membrane thickening, but also advanced lesions including
mesangiolysis, Kimmelstiel-Wilson-like nodules, arteriolar
hyalinosis, and tubulointerstitial disease [12].
Importantly this mouse model demonstrated that exces-
sive numbers of small blood vessels were induced around
glomeruli where normal vessels do not normally exist. Inter-
estingly, this is the same location where abnormal blood
vessels are observed in human diabetic kidney disease [12].
In addition, an increase in endothelial cell number in both
glomerular and peritubular lesions was found to exhibit
a proliferative response [12], which could be a potential
mechanism for the development of abnormal angiogenesis in
this mouse model. These studies suggested that the combi-
nation of high VEGF and low endothelial NO levels might be
responsible for the abnormal enhanced endothelial prolifera-
tion in this mouse model.
We next used the cell culture system to test our hypoth-
esis. Here we evaluated whether a lack of NO could alter
the proliferative effects of VEGF on endothelial cells [43].
Our primary finding was that blocking NO using either
an NO synthase inhibitor or high glucose condition could
enhance the proliferative response of endothelial cells to
VEGF [43]. Next issue was to investigate the mechanism.
VEGF is known to bind two different receptors, raising the
question of which onemight bemore important inmediating
these effects. Our study demonstrated that VEGFR2 was
primarily responsible for the cell proliferative response in
endothelial cells [43]. However, VEGFR1 was the primary
receptor responsible for stimulating NO since a VEGFR2
inhibitor failed to block NO production as well as eNOS
phosphorylation in response to VEGF in endothelial cells
[43]. Such findings are consistent with a 2001 study demon-
strating that distinct role between VEGFR1 and VEGFR2 in
nonendothelial cells [23]. Taken together, VEGF likely acts
on endothelial cells by two pathways; one elicits endothelial
proliferation through VEGFR2 while the other the activating
VEGFR1 for induction of NO, which negatively regulates the
VEGFR2-mediated proliferative response.
Nonetheless, endothelial cellsmight not be the only target
for this uncoupling condition. In our animalmodel, we found
that an increase in macrophage infiltration was observed
in glomeruli where VEGF expression was upregulated in
diabetic eNOSKO mice [17], suggesting that the uncoupling
condition could also mediate macrophage migration. In
this regard, NO administration could fix such VEGF-NO
balance, resulting in preventing macrophage migration if our
assumption is correct. In cultured macrophage cell line, we
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found that VEGF was able to induce macrophage migration
in Boyden chamber assay while administration of NO donor
alleviated such migration in response to VEGF [17]. Hence,
such uncoupling theory could be also applied to macrophage
infiltration in the diabetic nephropathy.
We also generated a mouse model in which we were able
to test the role of NO in the VEGFR2-mediated endothelial
proliferative response [44]. In this experiment, we utilized
the adenoassociated virus (AAV) to overexpress a VEGF
mutant (mtVEGF), which could only bind to VEGFR2.
Following the injection, mice underwent uninephrectomy
to amplify any renal lesions. Wild type (WT) mice were
also treated in the same way as a control group. We also
performed the study using mice lacking eNOS (eNOSKO)
to further allow us to specifically analyze the relationship
between VEGFR2 signal and endothelial NO in the kidney.
Overexpression of mtVEGF resulted in increased angio-
genesis and lowering of blood pressure in both types of
mice whereas such effects were greater in eNOSKO than
WT [44]. In addition, mtVEGF-AAV also caused severe
mesangial injury with increased proliferation associated with
elevated PDGF, PDGF-𝛽 receptor, and VEGFR2 in eNOSKO
mice compared to similarly treated WT mice [44]. These
data indicate that enhancing VEGFR2 signal could induce
aberrant angiogenesis which could be further exaggerated in
the absence of eNOS in the kidney.
6. Can a Low in VEGF Expression Also Be
Deleterious Even in Diabetic Nephropathy?
Our studies clearly demonstrate that an elevation in VEGF
may result in deleterious consequences in diabetic nephropa-
thy, primarily by overactivation of the VEGFR2 pathway in
the setting of endothelial dysfunction. However, as diabetic
nephropathy continues, there may actually be a reverse situa-
tion where VEGF expression falls in association with chronic
glomerular and tubular injury. For example, there are a couple
of studies showing thatVEGF expression is reduced in human
diabetic nephropathy within sclerotic areas and in nodular
lesions in the glomeruli [45, 46]. Baelde et al. documented
a 2.5-fold reduction in VEGF expression late stage diabetic
nephropathy in associationwith a loss of endothelial cells and
a reduction in podocytes [11]. Such interesting concept was
highlighted in an elegant study by Hohenstein and colleagues
in which VEGF activity was increased only in the mildly
injured glomeruli but significantly decreased inmore severely
injured glomeruli [2]. Given these facts, a low level of VEGF
is also undesirable in diabetes and is likely to manifest as the
kidney disease progresses.
Why could a lowering VEGF be also deleterious in the
diabetic nephropathy? It could be because normal kidney
requires a certain level of VEGF tomaintain integrity of renal
function. In general, normal kidney is composed of abundant
vessels so that a physiological level of VEGF is required to
maintain such vascular system. Perhaps, diabetic kidney does
so as well. In fact, we previously demonstrated that blocking
VEGF rather deteriorated tubulointerstitial injury. Impor-
tantly such injury was accompanied with a loss of peritubular
capillary, indicating that blocking VEGF made its level
too low so that peritubular capillary system could not be
maintained. Therefore a loss of peritubular capillary seems
to be a cause for deterioration of tubulointerstitial injury.
Recently, this notion was tested by other researchers by
using conditional mouse model. Sivaskandarajah et al. used
an inducible Cre-loxP gene-targeting system that enabled
genetic deletion of VEGF-A selectively from glomerular
podocytes of wild type mice, and then type 1 diabetes was
induced in mice using streptozotocin (STZ). Importantly,
this system allowed them to reduce VEGF level which was
lower than physiological level. As a consequence, a deletion of
VEGF resulted in more severe kidney injury in diabetes [47].
Hence, an important message could be that if VEGF is either
too low or too high, this factor could be deleterious. Rather,
maintaining VEGF at physical level could be protective in the
diabetic kidney.
7. How Could the Uncoupling Be Fixed?
First of all, we tested the effect of insulin therapy in this
model [12]. Controlling blood sugar was found to alleviate
the upregulation of VEGF and prevent the progression of
diabetic glomerular injury, suggesting that such beneficial
effect of insulin could be due in part to a fixation in VEGF-
NO balance.
We next examined the effect of the renin-angiotensin
system (RAS) blocking [48]. In contrast to diabetic wild
type mice, RAS blockades failed to slow the progression of
kidney injury in the diabetic eNOSKO mice. Unfortunately,
we did not address the issue of VEGF-NO balance in that
study. Nevertheless, similar refractoriness to ACEI/ARB in
diabetic nephropathywas also reported by other investigators
[49, 50]. Common nature of these three studies was that renal
injury was relatively severe in the animal models. While a
clear mechanism for refractoriness to ACEI/ARB remains
undetermined, ACEI/ARB may be no longer protective once
diabetic nephropathy progresses severely.
Finally, next compound we used was nicorandil, which
has two pharmacological actions; one is to donate NO while
the other action is to open K-channel dependently on ATP
[51]. We expected that by donating NO, nicorandil could fix
the balance of VEGF with NO. As expected, nicorandil was
found to exhibit some protection as evidenced by a reduction
in urinary protein excretion and slowing of the progression of
glomerular injury in accompany with an increase in urinary
NOx level [51]. These findings suggest that an NO donor,
nicorandil, could correct the balance of VEGF with NO and
be a therapeutic option to treat diabetic nephropathy in case
that kidney would be under the uncoupling condition.
8. Translation of Animal Study into
Clinical Medicine
It must be still immature and too preliminary to translate this
concept to clinicalmedicine. However, it might not be impos-
sible to apply this concept in the future study. In such case,
the first step could be examining renal VEGF and endothelial
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Figure 2: Uncoupling of VEGF with NO could be a pathway to
induce abnormal angiogenesis.Three distinct conditions commonly
cause uncoupling condition, leading to abnormal angiogenesis.
function. Urinary VEGF could be a marker of VEGF pro-
duction in the kidney as its increase in urine was found to
be positively associated with a degree of urinary albumin
excretion in patients with type 1 diabetes [18]. In turn,
endothelial function can be evaluated by several measures
which have been already established in clinical medicine.
For instance, urinary level of NOx could be a good marker
of endothelial dysfunction as it was found to be reduced in
type 2 diabetic patients with microalbuminuria compared to
those with normoalbuminuria [52]. Plasma von Willebrand
factor could be also used as a good marker for endothelial
function in diabetic patients with proteinuria [53–55]. Alter-
natively, the flow mediated vasodilatation or acetylcholine-
induced vasodilatation can be also clinically used to evaluate
endothelial function. Nevertheless, if any measures find the
combination of high VEGF with endothelial dysfunction,
such patients might be under the uncoupling condition. In
such cases, either donating NO or cautiously blocking of
VEGF could be considered as a therapeutic option.
9. Conclusions
In summary, physiological levels of VEGF are required for
the maintenance of normal renal architecture and function.
In case of diabetes, VEGF expression is induced and could
exhibit some deleterious effects. In particular when upregu-
lation of VEGF is coupled with endothelial dysfunction, such
combination can have a role in driving diabetic renal disease
(Figure 2). High levels of VEGF may have a role in abnormal
angiogenesis, macrophage activation, and even mesangial
expansion. In contrast, as disease progresses, VEGF levels
may fall, resulting in endothelial cell loss and capillary
rarefaction.
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